Datapoint: FDA Expands Cibinqo’s Atopic Dermatitis Approval

The FDA on Feb. 10 expanded Pfizer’s Cibinqo’s approved use in atopic dermatitis. Its use now includes patients age 12 to 18 with “with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable,” according to a Pfizer press release. For the treatment of atopic dermatitis, the JAK inhibitor currently holds covered or better status for 78% of all insured lives under the pharmacy benefit. About 22% of covered lives have preferred access to Cibinqo, largely with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 2/15/23

0 Comments
© 2025 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 17

Datapoint: Michigan Awards Contracts for New Duals Program

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 16

Datapoint: CMS Releases 2025 Star Ratings

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 15

Datapoint: Pfizer Scores Another Hemophilia Nod

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today